WO1998002157A1 - Topisch einsetzbare pharmazeutische formulierungen enthaltend als wirkstoff ein carbazolyl-(4)-oxy-propanolamin-derivat - Google Patents
Topisch einsetzbare pharmazeutische formulierungen enthaltend als wirkstoff ein carbazolyl-(4)-oxy-propanolamin-derivat Download PDFInfo
- Publication number
- WO1998002157A1 WO1998002157A1 PCT/EP1997/003602 EP9703602W WO9802157A1 WO 1998002157 A1 WO1998002157 A1 WO 1998002157A1 EP 9703602 W EP9703602 W EP 9703602W WO 9802157 A1 WO9802157 A1 WO 9802157A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbazolyl
- hydrogen
- treatment
- active ingredient
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
Definitions
- the present invention relates to pharmaceutical formulations which can be used topically and which have a carbazolyl- (4) -oxypropanolamine derivative of the general formula I as active ingredient
- R 1 and R 2 independently of one another denote hydrogen or the hydroxyl group, or contain their enantiomers or their pharmacologically acceptable salts.
- the invention also relates to new uses of these formulations for the topical treatment of peripheral circulatory disorders, in particular of the extremities, and of inflammation and skin wounds.
- Carbazolyl- (4) -oxypropanolamm derivatives are known to be therapeutically active compounds.
- EP 0 004 920 describes, in addition to other derivatives, the racemic compound of the general formula I with R and R " as hydrogen (Carvedilol *) as a medicament with vasodilating and ⁇ -receptor-blocking action, which are suitable for the treatment and prophylaxis of Cardiovascular and cardiac diseases such as hypertension and angina pectoris are suitable, enteral, parenteral and oral dosage forms are proposed.
- Raceric compounds of the formula I are also described by Yue et al. in "The Journal of Pharmacology and Experimental Therapeutics” 236 (1), pages 92-98 (1992). The authors report that Carvedilol * and, in particular in the carbazole structure or in the phenoxy compound, hydroxylated carvedilol derivatives have an antioxidative effect show and inhibit lipid peroxidation.
- the compounds of the general formula I, their pharmacologically acceptable salts, their enantiomers or their pharmacologically acceptable salts can be used for the topical treatment of locally peripheral blood circulation disorders, in particular of the extremities.
- Peripheral circulatory disorders in the extremities are often accompanied by numbness in the extremities, severely restricted mobility and swelling.
- the severity of circulatory disorders is very different and can have different causes.
- Frequent vasospastic attacks are treated with calcium antagonists or nitro compounds, which can lead to improved blood circulation due to their vasodilatory effects.
- prostaglandm E becomes intravenous administered or the flow conditions of the blood improved by controlled lowering of the fibrinogen, for example by subcutaneous snake venom application or hamodilution treatment.
- Particularly preferred are those hydroxylated carbazole derivatives whose hydroxyl groups are located in positions 1, 3, 6 or 8 of the carbazole chain.
- the compounds having a hydroxyl group in 1- or 3-position of the carbazole are very particularly suitable.
- Inflammation of the skin accounts for well over 50 ° 0 of all skin diseases. Their typical symptoms are reddening of the skin, blistering or excessive cornification, loss of elasticity of the skin, tearing of the skin, open bloody wounds, inflammation.
- hydrocortisone-containing ointments mainly hydrocortisone-containing ointments, light radiation and preparations from coal tar are used.
- anti-metabolites such as methotrexate or immunosuppressants such as Cyclosporm A or FK506 are used.
- These therapeutic agents are only partially effective, often they have no influence on the course of the disease.
- Particularly preferred are those hydroxylated carbazole derivatives whose hydroxyl group is located in positions 1, 3, 6 or 8 of the carbazole group.
- the compounds with hydroxyl group are particularly suitable in 1- or 3-position of the carbazole.
- EP 0 004 920 describes the preparation of the racemic compounds of the formula I with R and R as hydrogen, the separation of which into the optically active forms can be carried out by methods known per se.
- EP 0 127 099 describes the asymmetric synthesis of R- and S-carbazole derivatives of the general formula I with the radicals R 1 and R 2 as hydrogen, the enantiomers having a high optical purity being obtained.
- optically active phases are, for example, optically active polyacrylamides or Polymethacryia ide, e.g. T. also on silica gel (e.g.
- the carbazole derivatives of the general formula I obtained can be converted into pharmacologically acceptable salts by - preferably in an organic solvent - with the equivalent amount of an inorganic or organic acid, e.g. Hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, acetic acid, citric acid, maleic acid or benzoic acid.
- an inorganic or organic acid e.g. Hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, acetic acid, citric acid, maleic acid or benzoic acid.
- the carbazole derivatives of the formula I, their enantiomers or pharmacologically tolerable salts are formulated in a manner known per se using suitable pharmaceutical auxiliaries as a cream, ointment, gel, lotion, solution or spray.
- suitable pharmaceutical auxiliaries as a cream, ointment, gel, lotion, solution or spray.
- the medicaments contain one or more compounds of the general formula I in a total amount of 0.5-2% by weight. %.
- Suitable bases for ointments, creams or gels are, for example, petroleum jelly, paraffins, such as hard paraffin, or viscous paraffin, medium-chain triglycerides, natural waxes, wool wax, isopropyl myristate, highly disperse silicon dioxide, bentonite, starch, alginates, cellulose and cellulose ethers, sodium carboxymymethyl cellulose, poly lenglycols and others.
- Suitable solvents for lotions and solutions are water or water-alcohol mixtures.
- the agents according to the invention are applied to the skin.
- the amount of drug applied is generally about 0.01-10 mg / cm 2 skin.
- the compounds and pharmaceutical formulations according to the invention are used in particular for the treatment of Raynaud's disease, collagenosis (systemic lupus erythematosus, chronic polyarthritis, progressive systemic sclerosis), Sjorgen syndrome, thrombangitis obliterans and diabetic polyneuropathy.
- the compounds of the formula I and the formulations according to the invention are used for the treatment of dermatitis and eczema, in particular psoriasis and neurodermatitis.
- Example 1 Ointment with the following composition:
- Carvedilol is micronized using a jet mill or other device.
- the grinding obtained should contain 90% particles of the size 1-10 ⁇ .
- 100 g of the micronized active ingredient are mixed with 300 g of ointment base, e.g. B. ground with lanolin, placed on a roller mill and in this way a rub is produced.
- ointment base e.g. B. ground with lanolin
- the trituration thus obtained is made up to 10 kg with lanolin or another ointment base, stirred vigorously and passed over the roller mill for homogenization.
- This homogeneous mass is filled in m tubes. The tubes are folded and closed with a special machine.
- a patient with diagnosed secondary Raynaud's disease i.e. with severe circulatory disorders of the fingers, was treated with a formulation according to Example 1 for 4 weeks.
- the ointment was applied to the skin and was able to act for about 9 hours during the night. After a few days, the hands were functioning normally, i.e. the numbness of the fingers, their severely restricted mobility and the swelling had disappeared.
- the ointment was applied to the hand regularly throughout the day. After three weeks the wounds were closed, the fingers were painless and the hand was functional.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97931798A EP0910374A1 (de) | 1996-07-13 | 1997-07-08 | Topisch einsetzbare pharmazeutische formulierungen enthaltend als wirkstoff ein carbazolyl-(4)-oxy-propanolamin-derivat |
AU35426/97A AU3542697A (en) | 1996-07-13 | 1997-07-08 | Pharmaceutical formulations for topical application containing as an active ingredient carbazolyl-(4)-oxy-propanol amine derivate |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19628335.3 | 1996-07-13 | ||
DE19628335A DE19628335A1 (de) | 1996-07-13 | 1996-07-13 | Verwendung von Carbazolyl-(4)-oxy-propanolamin-Derivaten zur topischen Behandlung von peripheren Durchblutungsstörungen |
DE1997124752 DE19724752A1 (de) | 1997-04-24 | 1997-04-24 | Verwendung von Carbazolyl-(4)-oxy-propanolamin-Derivaten zur topischen Behandlung von Entzündungen und Wunden der Haut |
DE19724752.0 | 1997-04-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998002157A1 true WO1998002157A1 (de) | 1998-01-22 |
Family
ID=26027495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/003602 WO1998002157A1 (de) | 1996-07-13 | 1997-07-08 | Topisch einsetzbare pharmazeutische formulierungen enthaltend als wirkstoff ein carbazolyl-(4)-oxy-propanolamin-derivat |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0910374A1 (de) |
AU (1) | AU3542697A (de) |
WO (1) | WO1998002157A1 (de) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6582909B1 (en) | 1998-11-04 | 2003-06-24 | Genset, S.A. | APM1 biallelic markers and uses thereof |
US7626041B2 (en) | 2002-06-27 | 2009-12-01 | Smithkline Beecham (Cork) Ltd | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment |
US7649010B2 (en) | 2002-06-27 | 2010-01-19 | SmithKline Beechman Cork Limited | Carvedilol hydrobromide |
US7750036B2 (en) | 2003-11-25 | 2010-07-06 | Sb Pharmco Puerto Rico Inc. | Carvedilol salts, corresponding compositions, methods of delivery and/or treatment |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2337154A1 (de) * | 1973-07-18 | 1975-02-06 | Schering Ag | Neue carbazolderivate und verfahren zu ihrer herstellung |
DE3319027A1 (de) * | 1983-05-26 | 1984-11-29 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten |
WO1994012178A1 (en) * | 1992-12-01 | 1994-06-09 | Smithkline Beecham Corporation | Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds |
-
1997
- 1997-07-08 EP EP97931798A patent/EP0910374A1/de not_active Withdrawn
- 1997-07-08 WO PCT/EP1997/003602 patent/WO1998002157A1/de not_active Application Discontinuation
- 1997-07-08 AU AU35426/97A patent/AU3542697A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2337154A1 (de) * | 1973-07-18 | 1975-02-06 | Schering Ag | Neue carbazolderivate und verfahren zu ihrer herstellung |
DE3319027A1 (de) * | 1983-05-26 | 1984-11-29 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten |
WO1994012178A1 (en) * | 1992-12-01 | 1994-06-09 | Smithkline Beecham Corporation | Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds |
Non-Patent Citations (1)
Title |
---|
RUFFOLO ET AL.: "Hemodynamic differences between carvedilol and labetalol in the cutaneous circulation", EUR. J. CLIN. PHARMACOL., vol. 38, no. Supp2, 1990, pages S112 - S114, XP002044359 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6582909B1 (en) | 1998-11-04 | 2003-06-24 | Genset, S.A. | APM1 biallelic markers and uses thereof |
US7626041B2 (en) | 2002-06-27 | 2009-12-01 | Smithkline Beecham (Cork) Ltd | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment |
US7649010B2 (en) | 2002-06-27 | 2010-01-19 | SmithKline Beechman Cork Limited | Carvedilol hydrobromide |
US7759384B2 (en) | 2002-06-27 | 2010-07-20 | Smithkline Beecham (Cork) Limited | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment |
US7893100B2 (en) | 2002-06-27 | 2011-02-22 | Sb Pharmco Puerto Rico Inc. | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment |
US7902378B2 (en) | 2002-06-27 | 2011-03-08 | Smithkline Beecham (Cork) Limited | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment |
US7750036B2 (en) | 2003-11-25 | 2010-07-06 | Sb Pharmco Puerto Rico Inc. | Carvedilol salts, corresponding compositions, methods of delivery and/or treatment |
Also Published As
Publication number | Publication date |
---|---|
AU3542697A (en) | 1998-02-09 |
EP0910374A1 (de) | 1999-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2827018C2 (de) | ||
DE69732049T2 (de) | Pharmazeutische zubereitungen, enthaltend salze von hyaluronsäure und lokalanästhetika | |
EP0252286B1 (de) | Neue pharmazeutische Präparate zur topischen Applikation, Verfahren zu ihrer Herstellung und ihre Verwendung | |
DE69733086T2 (de) | Pharmazeutische zusammensetzungen welche kukui nuss öl enthalten | |
EP0367103B1 (de) | Topische Salbe | |
DE4013696A1 (de) | Salze des azelastins mit verbesserter loeslichkeit | |
EP0369263A2 (de) | Präparate zur topischen Behandlung von Hautkrankheiten | |
DE3030868C2 (de) | ||
WO1998002157A1 (de) | Topisch einsetzbare pharmazeutische formulierungen enthaltend als wirkstoff ein carbazolyl-(4)-oxy-propanolamin-derivat | |
DE4229050A1 (de) | Neue 9-Chlor-Prostaglandin-Ester und -amide | |
DE19724752A1 (de) | Verwendung von Carbazolyl-(4)-oxy-propanolamin-Derivaten zur topischen Behandlung von Entzündungen und Wunden der Haut | |
EP1507524B1 (de) | Topische verwendung von diuretika zur behandlung von schwellungen | |
DE2401446A1 (de) | Pharmazeutische zubereitungen zur linderung von hautproliferationserkrankungen | |
EP0383162A1 (de) | Verwendung einer Wirkstoffkombination zur Behandlung rheumatischer Erkrankungen | |
EP0996438A1 (de) | Verwendung von cis-6-hexadecensäure zur behandlung von psoriasis, allergien und autoimmunerkrankungen sowie bei trockener und empfindlicher haut | |
DE19628335A1 (de) | Verwendung von Carbazolyl-(4)-oxy-propanolamin-Derivaten zur topischen Behandlung von peripheren Durchblutungsstörungen | |
EP1087768B1 (de) | Verwendung von 1-(aminoalkyl)-3-chinoxalin-2-on-derivaten zur herstellung von als antioxidantien wirkenden zusammensetzungen | |
DE2411019C2 (de) | Verwendung von 1-(4-(1-Pyrrolidinyl)-2-butynyl)-2-pyrrolidinon oder 1-(2-Oxo-1-pyrrolidin)-4-(1-pyrrolidin)-2-butyn zur Behandlung von Glaucoma | |
EP0207421B1 (de) | Verwendung eines Retinoids zur Herstellung eines antikeratinisierenden Arzneimittels | |
DE19736265C2 (de) | Arzneimittel zur Behandlung von Hauterkrankungen | |
DE2713105A1 (de) | Dermatologisches arzneimittel | |
CH645269A5 (en) | Medicine for the skin, and process for its production | |
WO1989003215A1 (en) | Use of oxoquinazoline derivatives for the treatment of hyperlipidemia | |
EP1878433A1 (de) | Magmatithaltige topische Zusammensetzung | |
DE2818554A1 (de) | Zusammensetzung zur behandlung von schuppenflechte bei mensch und tier |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997931798 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997931798 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998505579 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997931798 Country of ref document: EP |